PX-102 or PX2060616, a non-steroidal FXR agonist developed to treat NASH, showed safety and good tolerance in a Phase 1 trial (ClinicalTrial.Gov identifier: NCT1998659 and NCT1998672). This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatohepatitis.